The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease
Background Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging. Objective To evaluate phen...
Gespeichert in:
Veröffentlicht in: | European journal of neurology 2021-05, Vol.28 (5), p.1557-1565 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1565 |
---|---|
container_issue | 5 |
container_start_page | 1557 |
container_title | European journal of neurology |
container_volume | 28 |
creator | Zimmermann, Milan Köhler, Leonie Kovarova, Marketa Lerche, Stefanie Schulte, Claudia Wurster, Isabel Machetanz, Gerrit Deuschle, Christian Hauser, Ann‐Kathrin Gasser, Thomas Berg, Daniela Schleicher, Erwin Maetzler, Walter Brockmann, Kathrin |
description | Background
Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging.
Objective
To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene.
Methods
We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings.
Results
PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale.
Conclusions
Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD.
Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. |
doi_str_mv | 10.1111/ene.14733 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2478588163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478588163</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</originalsourceid><addsrcrecordid>eNp1kc9uEzEQhy1ERdLAgRdAlrjAYRP_XXuPqAoUERUO5bxy1uPEYXcd7F1Q3osn6JPVYdsekBhZGh8-fZr5DUKvKVnSXCvoYUmF4vwZmlNR6oJyTp_nP5e0kJTQGbpM6UAIYYqRF2jGuRCVIGSOuts94Db0O_jlhxPeZRX-0oZhH7DpLfZDwg1E2MaQjr43LXbt6C0-xjCA78_d-RYSNvnhLljvPETsQsTfTPzh-xT6uz8JW5_AJHiJLpxpE7x66Av0_eP69uq62Hz99Pnqw6ZouNa8KIWuNDNalFIJKbnk4CxxumFGyaqRsKXQKAWSW8e4ZJqrLWGlNVZqbVnFF-jd5M3z_RwhDXXnUwNta3oIY6qZUDqjtOQZffsPeghjzJtmSlJWlkpUZabeT1STg0gRXH2MvjPxVFNSn29Q5-DqvzfI7JsH47jtwD6Rj6FnYDUBv3N0p_-b6vXNelLeA3HjkH8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2512667496</pqid></control><display><type>article</type><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</creator><creatorcontrib>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</creatorcontrib><description>Background
Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging.
Objective
To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene.
Methods
We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings.
Results
PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale.
Conclusions
Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD.
Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</description><identifier>ISSN: 1351-5101</identifier><identifier>EISSN: 1468-1331</identifier><identifier>DOI: 10.1111/ene.14733</identifier><identifier>PMID: 33449400</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Aging ; Biomarkers ; Cerebrospinal fluid ; Cognitive ability ; Fibroblast growth factor 23 ; Fibroblasts ; Genetic diversity ; genetic modifier ; Genetic variability ; Genetic variance ; Genotyping ; Growth factors ; Haplotypes ; Health risks ; Klotho ; Klotho protein ; Longevity ; longevity genes ; Metabolites ; Movement disorders ; Neurodegenerative diseases ; Parkinson's disease ; Parkinson´s disease ; Phenotypes ; Proteins ; Subgroups ; Vitamin D</subject><ispartof>European journal of neurology, 2021-05, Vol.28 (5), p.1557-1565</ispartof><rights>2021 The Authors. published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</citedby><cites>FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</cites><orcidid>0000-0001-7066-7749 ; 0000-0003-0157-5722</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fene.14733$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fene.14733$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33449400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zimmermann, Milan</creatorcontrib><creatorcontrib>Köhler, Leonie</creatorcontrib><creatorcontrib>Kovarova, Marketa</creatorcontrib><creatorcontrib>Lerche, Stefanie</creatorcontrib><creatorcontrib>Schulte, Claudia</creatorcontrib><creatorcontrib>Wurster, Isabel</creatorcontrib><creatorcontrib>Machetanz, Gerrit</creatorcontrib><creatorcontrib>Deuschle, Christian</creatorcontrib><creatorcontrib>Hauser, Ann‐Kathrin</creatorcontrib><creatorcontrib>Gasser, Thomas</creatorcontrib><creatorcontrib>Berg, Daniela</creatorcontrib><creatorcontrib>Schleicher, Erwin</creatorcontrib><creatorcontrib>Maetzler, Walter</creatorcontrib><creatorcontrib>Brockmann, Kathrin</creatorcontrib><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><title>European journal of neurology</title><addtitle>Eur J Neurol</addtitle><description>Background
Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging.
Objective
To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene.
Methods
We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings.
Results
PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale.
Conclusions
Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD.
Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</description><subject>Aging</subject><subject>Biomarkers</subject><subject>Cerebrospinal fluid</subject><subject>Cognitive ability</subject><subject>Fibroblast growth factor 23</subject><subject>Fibroblasts</subject><subject>Genetic diversity</subject><subject>genetic modifier</subject><subject>Genetic variability</subject><subject>Genetic variance</subject><subject>Genotyping</subject><subject>Growth factors</subject><subject>Haplotypes</subject><subject>Health risks</subject><subject>Klotho</subject><subject>Klotho protein</subject><subject>Longevity</subject><subject>longevity genes</subject><subject>Metabolites</subject><subject>Movement disorders</subject><subject>Neurodegenerative diseases</subject><subject>Parkinson's disease</subject><subject>Parkinson´s disease</subject><subject>Phenotypes</subject><subject>Proteins</subject><subject>Subgroups</subject><subject>Vitamin D</subject><issn>1351-5101</issn><issn>1468-1331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kc9uEzEQhy1ERdLAgRdAlrjAYRP_XXuPqAoUERUO5bxy1uPEYXcd7F1Q3osn6JPVYdsekBhZGh8-fZr5DUKvKVnSXCvoYUmF4vwZmlNR6oJyTp_nP5e0kJTQGbpM6UAIYYqRF2jGuRCVIGSOuts94Db0O_jlhxPeZRX-0oZhH7DpLfZDwg1E2MaQjr43LXbt6C0-xjCA78_d-RYSNvnhLljvPETsQsTfTPzh-xT6uz8JW5_AJHiJLpxpE7x66Av0_eP69uq62Hz99Pnqw6ZouNa8KIWuNDNalFIJKbnk4CxxumFGyaqRsKXQKAWSW8e4ZJqrLWGlNVZqbVnFF-jd5M3z_RwhDXXnUwNta3oIY6qZUDqjtOQZffsPeghjzJtmSlJWlkpUZabeT1STg0gRXH2MvjPxVFNSn29Q5-DqvzfI7JsH47jtwD6Rj6FnYDUBv3N0p_-b6vXNelLeA3HjkH8</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Zimmermann, Milan</creator><creator>Köhler, Leonie</creator><creator>Kovarova, Marketa</creator><creator>Lerche, Stefanie</creator><creator>Schulte, Claudia</creator><creator>Wurster, Isabel</creator><creator>Machetanz, Gerrit</creator><creator>Deuschle, Christian</creator><creator>Hauser, Ann‐Kathrin</creator><creator>Gasser, Thomas</creator><creator>Berg, Daniela</creator><creator>Schleicher, Erwin</creator><creator>Maetzler, Walter</creator><creator>Brockmann, Kathrin</creator><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7U7</scope><scope>C1K</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7066-7749</orcidid><orcidid>https://orcid.org/0000-0003-0157-5722</orcidid></search><sort><creationdate>202105</creationdate><title>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</title><author>Zimmermann, Milan ; Köhler, Leonie ; Kovarova, Marketa ; Lerche, Stefanie ; Schulte, Claudia ; Wurster, Isabel ; Machetanz, Gerrit ; Deuschle, Christian ; Hauser, Ann‐Kathrin ; Gasser, Thomas ; Berg, Daniela ; Schleicher, Erwin ; Maetzler, Walter ; Brockmann, Kathrin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3883-648982a84657455353efd0f8c2a759c5eb1ec77e53df2352837b026dad588d293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aging</topic><topic>Biomarkers</topic><topic>Cerebrospinal fluid</topic><topic>Cognitive ability</topic><topic>Fibroblast growth factor 23</topic><topic>Fibroblasts</topic><topic>Genetic diversity</topic><topic>genetic modifier</topic><topic>Genetic variability</topic><topic>Genetic variance</topic><topic>Genotyping</topic><topic>Growth factors</topic><topic>Haplotypes</topic><topic>Health risks</topic><topic>Klotho</topic><topic>Klotho protein</topic><topic>Longevity</topic><topic>longevity genes</topic><topic>Metabolites</topic><topic>Movement disorders</topic><topic>Neurodegenerative diseases</topic><topic>Parkinson's disease</topic><topic>Parkinson´s disease</topic><topic>Phenotypes</topic><topic>Proteins</topic><topic>Subgroups</topic><topic>Vitamin D</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zimmermann, Milan</creatorcontrib><creatorcontrib>Köhler, Leonie</creatorcontrib><creatorcontrib>Kovarova, Marketa</creatorcontrib><creatorcontrib>Lerche, Stefanie</creatorcontrib><creatorcontrib>Schulte, Claudia</creatorcontrib><creatorcontrib>Wurster, Isabel</creatorcontrib><creatorcontrib>Machetanz, Gerrit</creatorcontrib><creatorcontrib>Deuschle, Christian</creatorcontrib><creatorcontrib>Hauser, Ann‐Kathrin</creatorcontrib><creatorcontrib>Gasser, Thomas</creatorcontrib><creatorcontrib>Berg, Daniela</creatorcontrib><creatorcontrib>Schleicher, Erwin</creatorcontrib><creatorcontrib>Maetzler, Walter</creatorcontrib><creatorcontrib>Brockmann, Kathrin</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zimmermann, Milan</au><au>Köhler, Leonie</au><au>Kovarova, Marketa</au><au>Lerche, Stefanie</au><au>Schulte, Claudia</au><au>Wurster, Isabel</au><au>Machetanz, Gerrit</au><au>Deuschle, Christian</au><au>Hauser, Ann‐Kathrin</au><au>Gasser, Thomas</au><au>Berg, Daniela</au><au>Schleicher, Erwin</au><au>Maetzler, Walter</au><au>Brockmann, Kathrin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease</atitle><jtitle>European journal of neurology</jtitle><addtitle>Eur J Neurol</addtitle><date>2021-05</date><risdate>2021</risdate><volume>28</volume><issue>5</issue><spage>1557</spage><epage>1565</epage><pages>1557-1565</pages><issn>1351-5101</issn><eissn>1468-1331</eissn><abstract>Background
Parkinson´s disease (PD) has a large phenotypic variability, which may, at least partly, be genetically driven including alterations of gene products. Candidates might not only be proteins associated with disease risk but also pathways that play a role in aging.
Objective
To evaluate phenotype‐modifying effects of genetic variants in Klotho, a longevity gene.
Methods
We analyzed two longitudinal cohorts: one local cohort comprising 459 PD patients who underwent genotyping for the KL‐VS haplotype in Klotho including a subgroup of 125 PD patients and 50 healthy controls who underwent biochemical cerebrospinal fluid (CSF) analyses of Klotho and fibroblast growth factor 23 as well as vitamin D metabolites. The second cohort comprised 297 patients from the Parkinsonʼs Progression Markers Initiative (PPMI) for validation of genetic−clinical findings.
Results
PD patients carrying the KL‐VS haplotype demonstrated a shorter interval between PD onset and onset of cognitive impairment (both cohorts) and higher Unified Parkinson´s Disease Rating Scale part III (UPDRS III) scores (PPMI). CSF protein levels of Klotho and fibroblast growth factor 23 were lower in PD patients irrespective of gender compared to controls. Moreover, low CSF levels of Klotho were associated with higher scores in the UPDRS III and Hoehn and Yahr Scale.
Conclusions
Our results indicate that genetic variants in Klotho together with its corresponding CSF protein profiles are associated with aspects of disease severity in PD. These findings suggest that pathways associated with aging might be targets for future biomarker research in PD.
Low CSF levels of the longevity protein Klotho were associated with higher scores in Unified Parkinson's Disease Rating scale part II (UPDRS III). Patients with Parkinson's disease (PD) carrying the genetic “KL‐VS”‐variant demonstrated a shorter interval between PD onset and onset of cognitive impairment and higher UPDRS III scores. Genetic variants in Klotho along with its corresponding CSF protein profiles are associated with aspects of disease severity in PD.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>33449400</pmid><doi>10.1111/ene.14733</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0001-7066-7749</orcidid><orcidid>https://orcid.org/0000-0003-0157-5722</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1351-5101 |
ispartof | European journal of neurology, 2021-05, Vol.28 (5), p.1557-1565 |
issn | 1351-5101 1468-1331 |
language | eng |
recordid | cdi_proquest_miscellaneous_2478588163 |
source | Wiley Online Library Journals Frontfile Complete |
subjects | Aging Biomarkers Cerebrospinal fluid Cognitive ability Fibroblast growth factor 23 Fibroblasts Genetic diversity genetic modifier Genetic variability Genetic variance Genotyping Growth factors Haplotypes Health risks Klotho Klotho protein Longevity longevity genes Metabolites Movement disorders Neurodegenerative diseases Parkinson's disease Parkinson´s disease Phenotypes Proteins Subgroups Vitamin D |
title | The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for Parkinson´s disease |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T22%3A16%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20longevity%20gene%20Klotho%20and%20its%20cerebrospinal%20fluid%20protein%20profiles%20as%20a%20modifier%20for%20Parkinson%C2%B4s%20disease&rft.jtitle=European%20journal%20of%20neurology&rft.au=Zimmermann,%20Milan&rft.date=2021-05&rft.volume=28&rft.issue=5&rft.spage=1557&rft.epage=1565&rft.pages=1557-1565&rft.issn=1351-5101&rft.eissn=1468-1331&rft_id=info:doi/10.1111/ene.14733&rft_dat=%3Cproquest_cross%3E2478588163%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2512667496&rft_id=info:pmid/33449400&rfr_iscdi=true |